Zenopharm


Novel Cancer Therapeutics

Boron-based 4-hydroxytamoxifen and endoxifen prodrugs for treatment of breast cancer, several thiazole lead compounds that are potential anti-metastasis therapeutic regimens, and a novel anti-vasculature agent as inhibitor of tumor angiogenesis.